Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 ...

This stock is a great choice for cautious and aggressive investors.

Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Moderna earns the No. 356 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences EXAS, Genmab ADR GMAB and Krystal Biotech KRYS are among the top 5 highly rated stocks ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower on Friday afternoon, giving back a portion of the gains seen on Thursday. Here’s what investors need to know. What To Know: The stock spiked on ...

In the short term, Moderna (MRNA 0.57%) looks like a bad bet. It's coming off of the momentum of its COVID-19 vaccine, and doesn't have a lot of new ammo ready yet to expand in new directions. I think ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low ...

An update from Moderna ( ($MRNA) ) is now available. In a January 5, 2026 letter to shareholders, Moderna reviewed a challenging 2025 operating ...

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Friday after the company received Health Canada approval for the updated COVID-19 vaccine. What To Know: Health Canada authorized Moderna's ...